Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
22 Sep 2020
Estimate of the 2-year oncology workload generated by each new patient: A real-w...
Dr Silvio Ken Garattini - University of Udine, Udine, Italy
Estimate of the 2-year oncology workload generated by each new patient: A real-world study ( Dr Silvio Ken Garattini - University of Udine, Udine, Italy )
21 Sep 2020
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NS...
Dr Alex Spira and Dr Joshua Sabari
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC ( Dr Alex Spira and Dr Joshua Sabari )
21 Sep 2020
Impact of COVID-19 pandemic on cancer care: A global collaborative study
Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Ara...
Impact of COVID-19 pandemic on cancer care: A global collaborative study ( Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Arabia )
21 Sep 2020
MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer
Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK
MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer ( Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK )
21 Sep 2020
LungART: Radiotherapy after surgery for patients with non small cell lung cancer
Dr Cécile Le Péchoux - Gustave Roussy Cancer Campus, Villejuif, CEDEX, France
LungART: Radiotherapy after surgery for patients with non small cell lung cancer ( Dr Cécile Le Péchoux - Gustave Roussy Cancer Campus, Villejuif, CEDEX, France )
21 Sep 2020
Personalised molecularly matched therapies for carcinomas of unknown primary
Dr Jacob Adashek - University of South Florida, Tampa, USA
Personalised molecularly matched therapies for carcinomas of unknown primary ( Dr Jacob Adashek -  University of South Florida, Tampa, USA )
21 Sep 2020
Impact of COVID-19 on oncology professionals
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Impact of COVID-19 on oncology professionals ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
20 Sep 2020
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advan...
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
20 Sep 2020
Comparing real world evidence to phase III data on apalutamide for nmCRPC
Prof Heather Payne and Prof Stéphane Oudard
Comparing real world evidence to phase III data on apalutamide for nmCRPC ( Prof Heather Payne and Prof Stéphane Oudard )
19 Sep 2020
Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC
Dr Yungan Tao - Gustave Roussy Cancer Campus, Villejuif, France
Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC ( Dr Yungan Tao - Gustave Roussy Cancer Campus, Villejuif, France )
19 Sep 2020
The emerging importance of studying immune regulatory molecule expression patter...
Dr Jacob Adashek - The University of South Florida, Tampa, USA
The emerging importance of studying immune regulatory molecule expression patterns ( Dr Jacob Adashek -  The University of South Florida, Tampa, USA )
19 Sep 2020